Drug Profile
KB 3305
Alternative Names: A 348441; GR diabetes; KB003305; KB3305Latest Information Update: 21 Dec 2016
Price :
$50
*
At a glance
- Originator Karo Bio
- Class Antihyperglycaemics; Cholic acids; Estrenes
- Mechanism of Action Glucocorticoid receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 20 Aug 2015 No recent reports on development identified - Phase-II for Type-2 diabetes mellitus (PO)
- 04 Apr 2012 Phase-II clinical trials in Type-2 diabetes mellitus (PO)
- 16 Sep 2011 Final efficacy and adverse events data from a phase I trial in Type-2 diabetes mellitus presented at the 47th Annual meeting of the European Association for the Study of Diabetes (EASD-2011)